Prolacta Bioscience appoints David Steinberg as CFO
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
Subscribe To Our Newsletter & Stay Updated